CL2022003586A1 - Formulaciones de anticuerpo de activina a y métodos para utilizarlas - Google Patents
Formulaciones de anticuerpo de activina a y métodos para utilizarlasInfo
- Publication number
- CL2022003586A1 CL2022003586A1 CL2022003586A CL2022003586A CL2022003586A1 CL 2022003586 A1 CL2022003586 A1 CL 2022003586A1 CL 2022003586 A CL2022003586 A CL 2022003586A CL 2022003586 A CL2022003586 A CL 2022003586A CL 2022003586 A1 CL2022003586 A1 CL 2022003586A1
- Authority
- CL
- Chile
- Prior art keywords
- activin
- antibody
- methods
- antibody formulations
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040589P | 2020-06-18 | 2020-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003586A1 true CL2022003586A1 (es) | 2023-07-21 |
Family
ID=77168377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003586A CL2022003586A1 (es) | 2020-06-18 | 2022-12-15 | Formulaciones de anticuerpo de activina a y métodos para utilizarlas |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12472253B2 (enExample) |
| EP (1) | EP4168038A1 (enExample) |
| JP (2) | JP7850084B2 (enExample) |
| KR (1) | KR20230026407A (enExample) |
| CN (1) | CN116322768A (enExample) |
| AU (1) | AU2021293577A1 (enExample) |
| BR (1) | BR112022025700A2 (enExample) |
| CA (1) | CA3183316A1 (enExample) |
| CL (1) | CL2022003586A1 (enExample) |
| CO (1) | CO2023000264A2 (enExample) |
| IL (1) | IL299103A (enExample) |
| MX (1) | MX2022016403A (enExample) |
| WO (1) | WO2021257947A1 (enExample) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| US20180008672A1 (en) * | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| CN109641954A (zh) | 2016-08-29 | 2019-04-16 | 里珍纳龙药品有限公司 | 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法 |
| WO2018184692A1 (en) * | 2017-04-07 | 2018-10-11 | Ares Trading S.A. | Liquid pharmaceutical composition |
| MX2020004756A (es) * | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| IL276921B2 (en) * | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
-
2021
- 2021-06-18 EP EP21749377.4A patent/EP4168038A1/en active Pending
- 2021-06-18 CN CN202180059660.5A patent/CN116322768A/zh active Pending
- 2021-06-18 CA CA3183316A patent/CA3183316A1/en active Pending
- 2021-06-18 AU AU2021293577A patent/AU2021293577A1/en active Pending
- 2021-06-18 MX MX2022016403A patent/MX2022016403A/es unknown
- 2021-06-18 US US17/351,354 patent/US12472253B2/en active Active
- 2021-06-18 IL IL299103A patent/IL299103A/en unknown
- 2021-06-18 JP JP2022577556A patent/JP7850084B2/ja active Active
- 2021-06-18 WO PCT/US2021/038016 patent/WO2021257947A1/en not_active Ceased
- 2021-06-18 BR BR112022025700A patent/BR112022025700A2/pt unknown
- 2021-06-18 KR KR1020237001524A patent/KR20230026407A/ko active Pending
-
2022
- 2022-12-15 CL CL2022003586A patent/CL2022003586A1/es unknown
-
2023
- 2023-01-12 CO CONC2023/0000264A patent/CO2023000264A2/es unknown
-
2026
- 2026-04-10 JP JP2026064997A patent/JP2026108880A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022025700A2 (pt) | 2023-02-28 |
| AU2021293577A1 (en) | 2023-02-09 |
| MX2022016403A (es) | 2023-04-11 |
| JP2026108880A (ja) | 2026-06-30 |
| EP4168038A1 (en) | 2023-04-26 |
| KR20230026407A (ko) | 2023-02-24 |
| CA3183316A1 (en) | 2021-12-23 |
| IL299103A (en) | 2023-02-01 |
| US20210393779A1 (en) | 2021-12-23 |
| WO2021257947A1 (en) | 2021-12-23 |
| CO2023000264A2 (es) | 2023-01-26 |
| CN116322768A (zh) | 2023-06-23 |
| JP7850084B2 (ja) | 2026-04-22 |
| JP2023532203A (ja) | 2023-07-27 |
| US12472253B2 (en) | 2025-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CY1123909T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα κατα του υποδοχεα της ιντερλευκινης-6 (il-6r) | |
| CO2021016183A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3 | |
| CO2021011648A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-il-33 | |
| CL2019003032A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| UY33515A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ngf | |
| MX344294B (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). | |
| CO2020013552A2 (es) | Formulación de anticuerpos | |
| CL2023002560A1 (es) | Formulación de anticuerpos estable | |
| MX2021004331A (es) | Composiciones estables de semaglutida y usos de las mismas. | |
| MX2025007786A (es) | Compuestos organicos como inhibidores de nlrp3 | |
| CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas | |
| MX2021005910A (es) | Formulacion de proteina de alta concentracion. | |
| CO2023000264A2 (es) | Formulaciones de anticuerpo de activina a y métodos para utilizarlas | |
| UY33652A (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) | |
| CL2024003444A1 (es) | Formulación farmacéutica líquida estable que comprende un anticuerpo biespecífico anti-cd20/cd3 humano. | |
| EP4412643A4 (en) | COMPOSITIONS AND METHODS FOR REDUCING THE ADVERSE EFFECTS OF STORAGE, TRANSPORTATION, AND ADMINISTRATION OF ANTIGEN-CONTAINING FORMULATIONS | |
| CO2020013545A2 (es) | Formulación estable de anticuerpos | |
| CO2023014918A2 (es) | Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3 | |
| JOP20240074A1 (ar) | تركيبات إنزالوتاميد سائلة فموية | |
| BR112022002094A2 (pt) | Composição imunogênica | |
| JOP20240028A1 (ar) | جسيمات شحمية تتضمن ببتيدات تاو الفسفورية لتحفيز الاستجابات المناعية المستدامة |